...
首页> 外文期刊>Journal of Nanobiotechnology >A novel microfluidic wound model for testing antimicrobial agents against Staphylococcus pseudintermedius biofilms
【24h】

A novel microfluidic wound model for testing antimicrobial agents against Staphylococcus pseudintermedius biofilms

机译:一种新型的微流控伤口模型,用于测试抗伪葡萄球菌生物膜的抗菌剂

获取原文
           

摘要

Current methods for testing treatments for veterinary surgical site infections can successfully emulate elements of a chronic wound, but these are time consuming and costly, requiring specialized laboratory equipment and considerable space to house study animals. Microfluidic devices however, can be coated with collagen and maintained at basal body temperature, providing a more cost-effective and space-saving model of a chronic wound. Our study assesses the applicability of a new microfluidic model by testing the activity of DispersinB against biofilms of methicillin-resistant Staphylococcus pseudintermedius (MRSP); DispersinB has been shown to prevent biofilm growth of Staphylococcus epidermidis, another prominent wound colonizer. We successfully developed a microfluidic model to examine the effects of antimicrobial therapy on biofilms formed by organisms associated with wound infections in companion animals (e.g. MRSP). Although, we were unable to recapitulate previous findings that DispersinB-Gentamycin is highly effective against Staphylococcal biofilms using this model, we were able to confirm its effect in a microtitre plate. Differences in the experimental conditions likely account for this result (e.g. strains tested, flow conditions, treatment time, etc.). In the microtitre plate assay, DispersinB inhibited biofilm growth after a 24 hour period; there was an inverse relationship between the concentration of DispersinB-Gentamycin and the amount of biofilm remaining following treatment. Collagen-coated microtitre plates showed a similar result, but this did not correlate as well; collagen, the most abundant protein in the body may help to retain the biomass of treated biofilms. Our model may be useful in examining the effect of treatment on wound infections, although we acknowledge that in this model the test organisms may be more recalcitrant to antimicrobials than in other published systems. We contend that this may in fact better represent the conditions in vivo, where organisms associated with chronic wound infections are highly resistant to antimicrobials.
机译:测试兽医外科手术部位感染的治疗方法的当前方法可以成功地模仿慢性伤口的要素,但是这些既耗时又昂贵,需要专门的实验室设备和相当大的空间来容纳研究动物。然而,微流体装置可以涂有胶原蛋白并保持在基本体温下,从而提供了一种更具成本效益和节省空间的慢性伤口模型。我们的研究通过测试DispersinB对耐甲氧西林的伪中间葡萄球菌(MRSP)生物膜的活性来评估新的微流控模型的适用性;已经证明DispersinB可以阻止表皮葡萄球菌(另一种重要的伤口定植者)的生物膜生长。我们成功开发了一种微流控模型,以检查抗微生物治疗对伴侣动物(例如MRSP)伤口感染相关生物形成的生物膜的影响。虽然,我们无法使用该模型来概括先前的发现,即DispersinB-庆大霉素对葡萄球菌生物膜非常有效,但我们能够在微量滴定板上证实其效果。实验条件的差异可能是造成此结果的原因(例如测试的菌株,流动条件,处理时间等)。在微量滴定板分析中,DispersinB在24小时后抑制了生物膜的生长;处理后DispersinB-庆大霉素的浓度与剩余生物膜的数量成反比关系。胶原蛋白包被的微量滴定板显示出相似的结果,但是也没有相关性。胶原蛋白是人体中最丰富的蛋白质,可能有助于保留经过处理的生物膜的生物量。我们的模型可能有助于检查治疗方法对伤口感染的效果,尽管我们承认,在该模型中,与其他已发布的系统相比,测试生物对抗生素的抵抗力更高。我们认为,这实际上可以更好地代表体内条件,其中与慢性伤口感染相关的生物体对抗菌药物具有高度抗性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号